Sentinel lymph node biopsy for DCIS: Are we approaching consensus?

Annals of Surgical Oncology

Volumn 14, Issue 8, 2007, Pages 2179-2181

  Cody III, Hiram S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN; TAMOXIFEN;

AXILLARY LYMPH NODE; BREAST DUCT; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; EDITORIAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; NEEDLE BIOPSY; SENTINEL LYMPH NODE BIOPSY;

ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; AXILLA; BIOPSY; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FALSE NEGATIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; MASTECTOMY; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547459052     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9300-9     Document Type: Editorial

References (25)

1. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. Cancer 2006; 106:4-16
2. Cody HS, III. Sentinel lymph node biopsy for breast cancer: does anybody not need one? Ann Surg Oncol 2003; 10:1131-1132
3. Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Brit J Surg 2006; 93:539-546
4. King TA, Ganaraj A, Fey JV, et al. Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. Cancer 2004; 101:926-933
5. Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann Surg Oncol 2001; 8:275-277
6. Cody HS, Klauber-DeMore N, Borgen PI, et al. Is it really DCIS? Ann Surg Oncol 2001; 8:617-619
7. Silverstein MJ, Lagios MD, Martino S, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998; 16:1367-1373
8. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16:441-452
9. Julien J-P, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet 2000; 355:528-533
10. Leonard GD, Swain SM. Ductal Carcinoma In Situ, Complexities and Challenges. JNCI Cancer Spectrum 2004; 96:906-920
11. Schwartz GF, Solin LJ, Olivotto IA, et al. The consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999. The Breast Journal 2000; 6:4-13
12. Pendas S, Dauway E, Giuliano AE et al. Sentinel node biopsy in duct carcinoma in situ patients. Ann Surg Oncol 2000; 7:15-20
13. Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000; 7:636-642
14. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001; 67:513-519
15. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003; 138:309-313
16. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005; 200:516-526
17. Wilkie C, White L, Dupont E, et al. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. The American Journal of Surgery 2005; 190:563-566
18. Tamhane R, Dahlstrom JE, McCallum DD, et al. The clinical significance of cytokeratin-positive cells in lymph nodes at the time of mastectomy from patients with ductal carcinoma-in-situ. Ann Surg Oncol 2002; 9:999-1003
19. Lara JF, Young SM, Velilla RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003; 98:2105-2113
20. 4El-Tamer M, Chun J, Gill M, et al. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. Ann Surg Oncol 2005; 12:254-259
21. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218:497-502
22. Cody HS, III, Klauber-DeMore N, Borgen PI, et al. Is it really duct carcinoma in situ? Ann Surg Oncol 2001; 8:617-619
23. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in the treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993-2000
24. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347:567-575
25. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004; 240:462-468